154 related articles for article (PubMed ID: 36084418)
1. Development of novel cyanopyridines as PIM-1 kinase inhibitors with potent anti-prostate cancer activity: Synthesis, biological evaluation, nanoparticles formulation and molecular dynamics simulation.
Ibrahim MH; Harras MF; Mostafa SK; Mohyeldin SM; Al Kamaly O; Altwaijry N; Sabour R
Bioorg Chem; 2022 Dec; 129():106122. PubMed ID: 36084418
[TBL] [Abstract][Full Text] [Related]
2. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
3. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
Abouzid KAM; Al-Ansary GH; El-Naggar AM
Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341
[TBL] [Abstract][Full Text] [Related]
4. Nicotinonitrile-derived apoptotic inducers: Design, synthesis, X-ray crystal structure and Pim kinase inhibition.
Aboukhatwa SM; Ibrahim AO; Aoyama H; Al-Behery AS; Shaldam MA; El-Ashmawy G; Tawfik HO
Bioorg Chem; 2022 Dec; 129():106126. PubMed ID: 36108589
[TBL] [Abstract][Full Text] [Related]
5. New cyanopyridine-based scaffold as PIM-1 inhibitors and apoptotic inducers: Synthesis and SARs study.
Farrag AM; Ibrahim MH; Mehany ABM; Ismail MMF
Bioorg Chem; 2020 Dec; 105():104378. PubMed ID: 33099167
[TBL] [Abstract][Full Text] [Related]
6. Discovery of PIM-1 kinase inhibitors based on the 2,5-disubstituted 1,3,4-oxadiazole scaffold against prostate cancer: Design, synthesis, in vitro and in vivo cytotoxicity investigation.
Castanet AS; Nafie MS; Said SA; Arafa RK
Eur J Med Chem; 2023 Mar; 250():115220. PubMed ID: 36848846
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, Molecular Docking, and Biological Studies of New Heterocyclic Compounds Derived from β-Diketones as Novel EGFR and Pim-1 Inhibitors Endowed with AntitumorActivity.
Mohareb RM; Bagato NMA; Radwan IT
Anticancer Agents Med Chem; 2022; 22(14):2558-2576. PubMed ID: 35023461
[TBL] [Abstract][Full Text] [Related]
8. Discovery of new pyridine-quinoline hybrids as competitive and non-competitive PIM-1 kinase inhibitors with apoptosis induction and caspase 3/7 activation capabilities.
El-Miligy MMM; Abdelaziz ME; Fahmy SM; Ibrahim TM; Abu-Serie MM; Mahran MA; Hazzaa AA
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2152810. PubMed ID: 36629075
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and docking study of pyridine and thieno[2,3-b] pyridine derivatives as anticancer PIM-1 kinase inhibitors.
Abdelaziz ME; El-Miligy MMM; Fahmy SM; Mahran MA; Hazzaa AA
Bioorg Chem; 2018 Oct; 80():674-692. PubMed ID: 30064079
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis: A target for anticancer therapy with novel cyanopyridines.
Ismail MMF; Farrag AM; Harras MF; Ibrahim MH; Mehany ABM
Bioorg Chem; 2020 Jan; 94():103481. PubMed ID: 31837830
[TBL] [Abstract][Full Text] [Related]
11. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
El-Miligy MMM; Al-Kubeisi AK; El-Zemity SR; Nassra RA; Abu-Serie MM; Hazzaa AA
Bioorg Chem; 2021 Oct; 115():105171. PubMed ID: 34303896
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
Nafie MS; Amer AM; Mohamed AK; Tantawy ES
Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925
[TBL] [Abstract][Full Text] [Related]
13. Dual VEGFR-2/PIM-1 kinase inhibition towards surmounting the resistance to antiangiogenic agents via hybrid pyridine and thienopyridine-based scaffolds: Design, synthesis and biological evaluation.
Rizk OH; Teleb M; Abu-Serie MM; Shaaban OG
Bioorg Chem; 2019 Nov; 92():103189. PubMed ID: 31473473
[TBL] [Abstract][Full Text] [Related]
14. Imparting aromaticity to 2-pyridone derivatives by
Abdelaziz ME; El-Miligy MMM; Fahmy SM; Abu-Serie MM; Hazzaa AA; Mahran MA
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2304044. PubMed ID: 38230430
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and Pim-1 kinase inhibitors.
Li K; Li Y; Zhou D; Fan Y; Guo H; Ma T; Wen J; Liu D; Zhao L
Bioorg Med Chem; 2016 Apr; 24(8):1889-97. PubMed ID: 26979485
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of new thieno[2,3-b]pyridine derivatives as pim-1 inhibitors.
Naguib BH; El-Nassan HB
J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1718-25. PubMed ID: 27541740
[TBL] [Abstract][Full Text] [Related]
17. New pyrazolopyrimidine derivatives with anticancer activity: Design, synthesis, PIM-1 inhibition, molecular docking study and molecular dynamics.
Philoppes JN; Khedr MA; Hassan MHA; Kamel G; Lamie PF
Bioorg Chem; 2020 Jul; 100():103944. PubMed ID: 32450389
[TBL] [Abstract][Full Text] [Related]
18. Cyanopyridinone- and Cyanopyridine-Based Cancer Cell Pim-1 Inhibitors: Design, Synthesis, Radiolabeling, Biodistribution, and Molecular Modeling Simulation.
Mansour B; Salem YA; Attallah KM; El-Kawy OA; Ibrahim IT; Abdel-Aziz NI
ACS Omega; 2023 Jun; 8(22):19351-19366. PubMed ID: 37305261
[TBL] [Abstract][Full Text] [Related]
19. New Approaches for the Synthesis of Heterocyclic Compounds Corporating Benzo[d]imidazole as Anticancer Agents, Tyrosine, Pim-1 Kinases Inhibitions and their PAINS Evaluations.
Mohareb RM; Milad YR; Mostafa BM; El-Ansary RA
Anticancer Agents Med Chem; 2021; 21(3):327-342. PubMed ID: 32698742
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, molecular modeling, in vivo study and anticancer activity against prostate cancer of (+) (S)-naproxen derivatives.
Birgül K; Yıldırım Y; Karasulu HY; Karasulu E; Uba AI; Yelekçi K; Bekçi H; Cumaoğlu A; Kabasakal L; Yılmaz Ö; Küçükgüzel ŞG
Eur J Med Chem; 2020 Dec; 208():112841. PubMed ID: 32998089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]